NCT02403284

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 97 (actual)
• Sponsor: Phoenix VA Health Care System · Federal
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Detailed description

The specific aim of this study is to determine the ability of subacute liraglutide administration to protect against dietary lipid induced peripheral insulin resistance in non-diabetic subjects who have normal glucose tolerance. Recent data from our laboratory and others suggest that high fat meals, enriched with saturated fatty acids (SFA) in particular, have a unique and profound ability to induce rapid (in ≤ 24 hr) and profound onset of insulin resistance in humans. This is presumably mediated in part through delivery of lipids and lipid products generated during postprandial lipolysis into non-adipose tissue. This unique model therefore provides an excellent platform to test agents for their ability to inhibit dietary induced insulin resistance. As we and others have demonstrated the ability of GLP-1 receptor agonists to markedly suppress postprandial lipid elevations and to modify lipid metabolism, we hypothesize that liraglutide may be an effective agent to inhibit development of dietary induced insulin resistance.

Conditions

• Insulin Resistance

Interventions

Type	Name	Description
DRUG	Liraglutide	Subcutaneous injection by patient
DRUG	Sugar Pill	Subcutaneous injection daily

Timeline

• Start date: 2013-03-01
• Primary completion: 2021-04-28
• Completion: 2023-11-01
• First posted: 2015-03-31
• Last updated: 2024-07-22

Locations

1 site across 1 country: United States